Montioli Riccardo, Roncador Alessandro, Oppici Elisa, Mandrile Giorgia, Giachino Daniela Francesca, Cellini Barbara, Borri Voltattorni Carla
Department of Life Sciences and Reproduction, University of Verona, Verona, Italy and.
Department of Clinical and Biological Sciences, University of Torino, Torino, Italy.
Hum Mol Genet. 2014 Nov 15;23(22):5998-6007. doi: 10.1093/hmg/ddu329. Epub 2014 Jul 2.
Primary Hyperoxaluria type I (PH1) is a rare disease due to the deficit of peroxisomal alanine:glyoxylate aminotransferase (AGT), a homodimeric pyridoxal-5'-phosphate (PLP) enzyme present in humans as major (Ma) and minor (Mi) allele. PH1-causing mutations are mostly missense identified in both homozygous and compound heterozygous patients. Until now, the pathogenesis of PH1 has been only studied by approaches mimicking homozygous patients, whereas the molecular aspects of the genotype-enzymatic-clinical phenotype relationship in compound heterozygous patients are completely unknown. Here, for the first time, we elucidate the enzymatic phenotype linked to the S81L mutation on AGT-Ma, relative to a PLP-binding residue, and how it changes when the most common mutation G170R on AGT-Mi, known to cause AGT mistargeting without affecting the enzyme functionality, is present in the second allele. By using a bicistronic eukaryotic expression vector, we demonstrate that (i) S81L-Ma is mainly in its apo-form and has a significant peroxisomal localization and (ii) S81L and G170R monomers interact giving rise to the G170R-Mi/S81L-Ma holo-form, which is imported into peroxisomes and exhibits an enhanced functionality with respect to the parental enzymes. These data, integrated with the biochemical features of the heterodimer and the homodimeric counterparts in their purified recombinant form, (i) highlight the molecular basis of the pathogenicity of S81L-Ma and (ii) provide evidence for a positive interallelic complementation between the S81L and G170R monomers. Our study represents a valid approach to investigate the molecular pathogenesis of PH1 in compound heterozygous patients.
I型原发性高草酸尿症(PH1)是一种罕见疾病,由过氧化物酶体丙氨酸:乙醛酸转氨酶(AGT)缺乏引起,AGT是一种同源二聚体的磷酸吡哆醛(PLP)酶,在人类中以主要(Ma)和次要(Mi)等位基因形式存在。导致PH1的突变大多为错义突变,在纯合子和复合杂合子患者中均可发现。到目前为止,PH1的发病机制仅通过模拟纯合子患者的方法进行研究,而复合杂合子患者中基因型-酶-临床表型关系的分子层面完全未知。在此,我们首次阐明了与AGT-Ma上S81L突变相关的酶表型,该突变涉及一个PLP结合残基,以及当AGT-Mi上最常见的突变G170R(已知会导致AGT错误定位但不影响酶功能)存在于第二个等位基因时,这种酶表型会如何变化。通过使用双顺反子真核表达载体,我们证明:(i)S81L-Ma主要处于脱辅基形式,具有显著的过氧化物酶体定位;(ii)S81L和G170R单体相互作用产生G170R-Mi/S81L-Ma全酶形式,该全酶形式被导入过氧化物酶体,并相对于亲本酶表现出增强的功能。这些数据,结合其纯化重组形式的异二聚体和同二聚体对应物的生化特征,(i)突出了S81L-Ma致病性的分子基础;(ii)为S81L和G170R单体之间的正向等位基因互补提供了证据。我们的研究代表了一种研究复合杂合子患者中PH1分子发病机制的有效方法。